Overview
- Elon Musk said the company is ready to proceed pending regulatory steps and that initial outcomes are expected to be low resolution with improvements over time.
- Reporting indicates the FDA has cleared early human studies this year for the visual-cortex implant, which remains in an experimental phase.
- Blindsight’s design uses surgically inserted microthreads connected to a skull-mounted transmitter and a wirelessly rechargeable battery to deliver targeted cortical stimulation.
- The system targets people who lost sight due to eye or optic-nerve damage and could potentially produce percepts even in those born blind because it bypasses the eyes.
- Neuralink cites prior macaque studies and its Telepathy human implant demonstrations, while experts caution that safety, efficacy and meaningful vision gains require multi-year validation.